CA
SAGE

Continuum Advisory’s Sage Therapeutics SAGE Stock Holding History

Continuum Advisory’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-50
Closed -$398 – 1344
2025
Q1 		$398 Hold
50
– – ﹤0.01% 1591
2024
Q4 		$272 Hold
50
– – ﹤0.01% 1805
2024
Q3 		$269 Hold
50
– – ﹤0.01% 1866
2024
Q2 		$543 Hold
50
– – ﹤0.01% 1584
2024
Q1 		$617 Buy
+50
New +$1.15K ﹤0.01% 1566

Other funds holding SAGE

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Continuum Advisory's SAGE Position: Q2 2025 in Review

Continuum Advisory sold out of Sage Therapeutics (SAGE) in Q2 2025, closing a stake of 50 shares — an estimated $398 sold.

Continuum Advisory first reported a position in SAGE in Q1 2024 and held it in 5 quarters. The position peaked at $617 in Q1 2024. 192 funds tracked by Wall St. Rank hold SAGE as of Q2 2025.

  • Continuum Advisory reported no remaining Sage Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Continuum Advisory sold 50 Sage Therapeutics shares in Q2 2025, an estimated $398.
  • Continuum Advisory first reported a position in Sage Therapeutics in Q1 2024 and held it in 5 quarters.
  • Continuum Advisory's Sage Therapeutics position peaked at $617 in Q1 2024.
  • 192 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2025.

Based on Continuum Advisory's 13F filing for Q2 2025, filed 13 Aug 2025.